Keywords: AASLD; American Association for the Study of Liver Diseases; AIH; autoimmune hepatitis; AILDs; autoimmune liver diseases; BMD; bone mineral densitometry; CCA; cholangiocarcinoma; COIs; clinical outcome indicators; CRC; colorectal cancer; DAAs; direct acti
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Hepatitis B virus (HBV); Hepatitis C virus (HCV); Breast cancer; Chemotherapy; HBV/HCV reactivation; Toxicity; HCV; hepatitis C virus; CHC; chronic hepatitis C; HBV; hepatitis B virus; CHB; chronic hepatitis B; DAAs; direct-acting antiviral agents; ER; es
Keywords: Alcoholic liver disease; DAAs; HBV recurrence; Immunosuppression; Liver transplantation;
Keywords: Trust; Cloud computing; Opinion leaders; Troll; Reputation; API; Application Programming Interface; APIaaS; API as a Service; Baas; Backend as a Service; B2C; Business to Customer; C2C; Customer to Customer; DaaS; Data as a Service; DBaaS; Database as a S
Keywords: HCV; hepatitis C; LT; liver transplantation; DDI; drug-drug interactions; DAAs; direct-acting antivirals; PegINF; peginterferon; RBV; ribavirin; MELD; model of end-stage liver disease; PI; protease inhibitor; PR; peginterferon plus ribavirin; SAEs; seriou
Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfected patients treated with direct antiviral agents (DAAs)
Keywords: HCV; DAAs; Diabetes; Hepatokines; Adipokines; Cytokines;
State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015
Keywords: DAAs; direct-acting antivirals; hepatitis C; Medicaid; sofosbuvir; specialty drugs;
Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice
Keywords: HCV; Glecaprevir; Pibrentasvir; Sofosbuvir; NS5A inhibitor resistance associated variant; P32 deletion; Human hepatocyte chimeric mouse; ASV; asunaprevir; DAAs; Direct-acting antivirals; DCV; daclatasvir; GLE; glecaprevir; HCV; hepatitis C virus; LDV; led
Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse
Keywords: Hepatitis C; pediatrics; prevalence; inpatient; substance abuse; DAAs; Direct-acting antivirals; HCV; Hepatitis C virus; KID; Kids' Inpatient Database;
Interleukin-7 augments CD8+ T cells function and promotes viral clearance in chronic hepatitis C virus infection
Keywords: ALT; alanine aminotransferase; CCK-8; Cell Counting Kit-8; DAAs; direct-acting antivirals; ELISA; enzyme-linked immunosorbent assay; HBV; hepatitis B virus; HCV; hepatitis C virus; HCVcc; HCV in cell culture; HIV; human immunodeficiency virus; IFN; interf
Dysregulation of fibrosis related genes in HCV induced liver disease
Keywords: Alb; Albumin; ALK PH; Alkaline phosphatase; ALT; Alanine amino transferase; APO; Apolipoprotein; AST; Aspartate transaminase; AUC; Area Under Curve; BIL.D; Direct bilirubin; BIL T; Total bilirubin; BMI; Body mass index; cDNA; Complementary DNA; CTGF; Conn
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
Keywords: Direct-acting antivirals; Resistance associated substitutions; DAAs; direct-acting antiviral agents; NI; nucleoside/nucleotide inhibitor; PI; protease inhibitor; RAS; resistance-associated substitution; SVR; sustained virologic response; SVR12; sustained
Hypericin inhibits hepatitis C virus replication via deacetylation and down-regulation of heme oxygenase-1
Keywords: Hepatitis C virus (HCV); Hypericin; Epigenetic; Deacetylation; HCV; Hepatitis C virus; NS5A; non-structure protein 5A; NS3; non-structure protein 3; HO-1; heme oxygenase 1; 5-Aza-dC; 5-aza-2â²-deoxycytidine; DAAs; direct acting antivirals; PCR; polymeras
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir
Keywords: POLARIS-1 and POLARIS-4; Fatigue; Work Productivity; Health Utility; Vitality; CLDQ-HCV; Chronic Liver Disease Questionnaire-HCV Version; DAAs; direct-acting antiviral agents; FACIT-F; Functional Assessment of Chronic Illness Therapy-Fatigue; HCV; hepatit
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
Keywords: RESIST-HCV; Liver Cancer Risk; Reduction; Sofosbuvir; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; DAAs; direct-antiviral agents; EGS; esophageal gastroscopy; EV; esophageal varices; HCC; hepatocellular carcinoma; HCV; hepatitis C virus;
Respiratory adverse effects of Sofosbuvir-based regimens for treatment of chronic hepatitis C virus
Keywords: BHR; bronchial hyperresponsiveness; DAAs; direct-acting antivirals; FEF25-75%; forced expiratory flow in the middle part of FVC maneuver; FEV1; forced expiratory volume in 1st second; FVC; forced vital capacity; HCC; hepatocellular carcinoma; HCV; hepat
Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major
Keywords: PRC; packed red blood cells; HIV; human immunodeficiency virus; DAAs; direct acting antivirals; SVR; sustained virological response; RNA; ribonucleic acid; VAS; visual analogue scale; RVR; rapid virological response; EBR; elbasvir; GZR; grazoprevir; SD; s
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256
Keywords: Phase 1 monotherapy study; Drug resistance profile; Genotype 1; Sequencing; DAAs; Direct acting antivirals; PI; protease inhibitor; RAS; resistance associated substitution; SVR; sustained virologic response;
Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach
Keywords: 2D; Two-Dimensional; 3D; Three-Dimensional; DAAs; Direct Acting Antivirals; FDA; Food and Drug Administration; HCV; Hepatitis C Virus; HBV; Hepatitis B Virus; HCMV; Human Cytomegalo Virus; HIV; Human Immunodeficiency Virus; HSV; Herpes Simplex Virus; Inf
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
Keywords: Chronic hepatitis C; DAA treatment; Immune response; miRNA-122; HCV; hepatitis C virus; IP-10; interferon gamma-induced protein; CHC; chronic hepatitis C; DAAs; direct acting antivirals; SVR; sustained virological response; miR-122; microRNA-122; RAS; res
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Keywords: Direct-acting antivirals; DAAs; SVR; Safety; HIV/HCV co-infection; Real world;
Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4+ T cells contributes to viral persistence in chronic hepatitis C
Keywords: BTLA; B and T lymphocyte attenuator; CTLA-4; cytotoxic T-lymphocyte antigen 4; DAAs; direct-acting antiviral agents; ELISA; enzyme-linked immunosorbent assay; FBS; fetal bovine serum; Gal-9; Galectin-9; HBV; hepatitis B virus; HCV; hepatitis C virus; HCVc
Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity
Keywords: Antibody-dependent cell cytotoxicity; Anti-viral agents; Disintegrins; HCV; Natural killer; FcγRIII; ADAM-17; MMP9; CD69; DAAs;
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Keywords: HCV; hepatitis C virus; PWID; people who inject drugs; DAAs; directly acting antivirals; OST; opioid substitution therapy; OR; odds ratio; CI; confidence interval; HIV; human immunodeficiency virus; RVR; rapid virological response; RNA; ribonucleic acid;
Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
Keywords: ALT; alanine aminotransferase; CHC; chronic hepatitis C; CI; confidence interval; DAAs; direct-acting antiviral agents; DCV; daclatasvir; EASL; The European Association for the Study of the Liver; GT; Genotype; HCC; hepatocellular carcinoma; HCV; hepatiti
Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication
Keywords: HCV; hepatitis C virus; pegIFN-α; pegylated interferon alpha; DAAs; direct acting antivirals; BCLC; Barcelona ClÃnic Liver Cancer; IF; immunofluorescence; HCVpp; HCV pseudoparticles; HCVcc; HCV cell culture; JFH1; Japanese fulminant hepatitis 1; Apo; ap
Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-λ1 contributes to its anti-HCV activity in human hepatoma cells
Keywords: IFN-λ; Hepatitis C virus; Autophagy; ATG5; GABARAP; IFN-λ; interferon-λ; HCV; hepatitis C virus; LC3B; microtubule-associated protein 1 light chain 3B; HCC; hepatocellular carcinoma; DAAs; directly acting antivirals; SVR; sustained virological response
Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus
Keywords: Hepatitis C virus; Classical swine fever virus; Antivirals; Glycoconjugates; Analogs of glycosyltransferase substrates; ILVGQOUWGLOKMP-UGBKOBOPSA-N; MJILQYTZKHJMKK-JXMOPYPQSA-N; ILVGQOUWGLOKMP-KWMWGXAVSA-N; SDHKEMBDVHATRV-QGWGQYCPSA-N; KEVMAVJXDKVYJN-UNOI
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection
Keywords: Hepatitis C virus; Extrahepatic manifestations; DAAs; Rituximab;
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C
Keywords: CHC; chronic hepatitis C; HCV; Hepatitis C virus; PEG-IFN; pegylated interferon alfa; RBV; ribavirin; DAAs; direct-acting antiviral agents; GT1; genotype 1; GT4; genotype 4; IQR; inter-quartile range; OR; odds ratio; HCV; IL28B; Liver stiffness; Fibrosis
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
Keywords: HCV; hepatitis C virus; HCV-EHMs; HCV-extrahepatic manifestations; IFN; interferon; CV; cryoglobulinemic vasculitis; AVT; antiviral therapy; Peg-IFN; pegylated interferon; RBV; ribavirin; DAAs; direct-acting antiviral agents; FDA; food and drug administra
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015
Keywords: Hepatitis C; HCV treatment; Direct-acting antivirals; DAAs; Drug prescription data; Health insurance data; Pharmacy sales price; Elimination;
Case ReportLiver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Keywords: HCV; Hepatitis C virus; HCC; hepatocellular carcinoma; DAAs; direct-acting antivirals; HIV; human immunodeficiency virus; MELD; Model for End-stage Liver Disease; RNA; ribonucleic acid; SIRS; systemic inflammatory response syndrome; HBV; Hepatitis B virus
Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents
Keywords: Cirrhosis; DAAs; diabetes; HCV; HIV/HCV;
Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries
Keywords: HCV variability; DAAs; Resistance-associated variants;
Research ArticleHepatitis C reinfection after sustained virological response
Keywords: HCV; hepatitis C virus; PWID; people who inject drugs; SVR; sustained virological response; IDU; injecting drug use; DAAs; direct-acting antivirals; RNA; ribonucleic acid; OST; opioid substitution treatment; RVR; rapid virological response; E1; envelope 1
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma
Keywords: Liquid chromatography; Tandem mass spectrometry; HCV; DAAs; TDM; Multiplexed;
Research ArticlePharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
Keywords: HCV; hepatitis C Virus; ESRD; end-stage renal disease; DAAs; direct-acting anti-HCV agents; SOF; sofosbuvir; LDV; ledipasvir; SOF-007TP; sofosbuvir uridine-triphosphate; SOF-007; predominant sofosbuvir inactive metabolite GS-331007; QD; once daily; TIW; t
Research ArticleHCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Keywords: HCV; hepatitis C virus; DAAs; direct-acting antiviral agents; SVR; sustained virological response; HCV; Viral kinetics; Mathematical modeling; SVR; Duration of therapy;
Research ArticleDelisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Keywords: DAAs; direct acting antivirals; HCV; hepatitis C virus; LT; liver transplantation; HCC; hepatocellular carcinoma; MELD; model for end-stage liver disease; ELITA; European Liver and Intestine Transplant Association; HIV; human immunodeficiency virus; HBV;
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Keywords: AE; adverse events; DAAs; direct-acting antiviral agents; DCV; daclatasvir; EOT; end of treatment; GFR; glomerular filtration rate; HCV; hepatitis C virus; HIV; human immunodeficiency virus; IMS; immunosuppressive; LLOQ; lower limit of quantification; LT;
Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations – An Egyptian perspective
Keywords: DAAs; Cryoglobulinemia; Chronic kidney Disease; Dialysis; Transplantation
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Keywords: Direct-Acting Antivirals; ION-1; ION-2; ION-3; DAAs; direct-acting antiviral agents; HCV; hepatitis C virus; LiPA; Line Probe Assay; NI; nucleotide inhibitor; PI; protease inhibitor; RAS; resistance-associated substitution; SVR; sustained virologic respon
Near full length hepatitis C virus genome reconstruction by next generation sequencing based on genotype-independent amplification
Keywords: DAAs; Deep-sequencing; Full genome reconstruction; HCV; Modified SISPA approach
Research ArticleSofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
Keywords: HCV; hepatitis C virus; PegIFNα; pegylated interferon; RBV; ribavirin; SVR; sustained virologic response; DAAs; direct-acting antiviral agents; APRI; aminotransferase:platelet ratio index; ULN; upper limit of normal; LLOQ; lower limit of quantitation; NI
Research ArticleSafety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET
Keywords: HCV; hepatitis C virus; DAAs; direct-acting antiviral agents; PegIFNα; pegylated interferon alfa; AE; adverse event; SAE; serious adverse event; SVR; sustained virologic response; DRESS; drug reaction with eosinophilia and systemic symptoms; Hepatitis C;
Research ArticleTrends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment
Keywords: HCV; hepatitis C virus; NSW; New South Wales; BC; British Columbia; SVR; sustained virological response; DAAs; direct-acting antiviral agents; HAART; highly active anti-retroviral therapy; HPS; Health Protection Scotland; NRS; National Records of Scotland
Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold
Keywords: HCV; RdRp; Thumb site I; Indole; Anti-viral; Heterocycle; HCV; hepatitis C virus; RdRp; RNA-depended-RNA-polymerase; WHO; World Health Organization; HCC; hepatocellular carcinoma; SOC; standard of care; PEG-IFN-α; pegalated α-interferon; RVB; Ribavi
Liver, pancreas and biliary tractDefer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
Keywords: Boceprevir; Chronic hepatitis C genotype 1; DAAs; Telaprevir; Therapy decision; Real-life data;